GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Mochida Pharmaceutical Co 4534.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

3,255

+2.84%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2026

Revenue

¥116.95bn

FY2017FY2026

Net income

¥7.90bn

FY2017FY2026

Free cash flow

−¥10.04bn

FY2017FY2026

Shareholders' equity

¥140.33bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue¥116.95bn¥105.16bn¥102.89bn¥103.26bn¥110.18bn¥103.00bn¥101.80bn¥109.65bn¥106.75bn¥97.35bn
Gross profit¥56.26bn¥53.79bn¥52.07bn¥55.12bn¥59.55bn¥54.79bn¥51.92bn¥54.17bn¥53.57bn¥56.31bn
Research and development—¥11.68bn¥12.55bn¥13.28bn¥12.29bn¥10.85bn¥11.88bn¥13.00bn¥11.91bn¥15.23bn
Operating income¥10.15bn¥8.13bn¥5.80bn¥8.51bn¥14.39bn¥12.00bn¥8.81bn¥10.59bn¥11.66bn¥11.37bn
Net income¥7.90bn¥5.68bn¥4.55bn¥6.65bn¥10.57bn¥8.59bn¥4.60bn¥8.44bn¥9.02bn¥8.53bn
Diluted earnings per share223.20160.37128.26186.97285.66225.05119.06215.60227.27214.74

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets¥182.72bn¥163.56bn¥162.30bn¥161.04bn¥165.93bn¥165.88bn¥160.35bn¥163.59bn¥158.26bn¥148.37bn
Cash and short-term investments¥31.06bn¥51.15bn¥46.79bn¥60.51bn¥61.91bn¥63.49bn¥61.29bn¥59.03bn¥53.68bn¥54.31bn
Total liabilities¥42.39bn¥32.87bn¥34.33bn¥34.26bn¥37.28bn¥38.90bn¥39.69bn¥38.48bn¥38.57bn¥36.50bn
Debt¥10.00bn¥342.0m¥369.0m¥178.0m————¥46.0m¥47.0m
Shareholders' equity¥140.33bn¥130.69bn¥127.97bn¥126.78bn¥128.65bn¥126.97bn¥120.67bn¥125.11bn¥119.69bn¥111.87bn
Shares outstanding35m35m35m36m37m38m39m39m40m40m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−¥7.35bn¥9.35bn−¥7.48bn¥7.30bn¥7.46bn¥9.20bn¥9.35bn¥12.56bn¥3.28bn¥5.58bn
Capital spending−¥2.69bn−¥2.16bn−¥2.30bn−¥2.17bn−¥3.10bn−¥2.09bn−¥1.96bn−¥1.37bn−¥1.09bn−¥1.11bn
Free cash flow−¥10.04bn¥7.19bn−¥9.78bn¥5.13bn¥4.36bn¥7.11bn¥7.39bn¥11.20bn¥2.19bn¥4.48bn
Dividends paid−¥2.83bn−¥2.83bn−¥2.89bn−¥3.37bn−¥3.44bn−¥3.10bn−¥3.34bn−¥3.52bn−¥3.42bn−¥2.73bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥31.72bn¥29.46bn¥32.50bn¥28.35bn¥26.63bn¥24.43bn¥29.64bn¥25.69bn
Gross profit¥14.69bn¥14.40bn¥15.01bn¥13.23bn¥13.63bn¥12.34bn¥16.16bn¥12.33bn
Operating income¥3.56bn¥2.62bn¥2.56bn¥2.40bn¥2.57bn¥883.0m¥3.45bn¥1.60bn
Net income¥3.18bn¥1.56bn¥2.49bn¥1.96bn¥1.89bn¥80.0m¥2.78bn¥1.27bn
Diluted earnings per share89.7544.0970.1355.3553.432.2678.4235.85
Total assets¥181.42bn¥182.72bn¥182.22bn¥165.72bn¥161.74bn¥163.56bn¥166.05bn¥158.43bn
Cash and short-term investments¥28.41bn¥31.06bn¥41.50bn¥52.72bn¥54.69bn¥51.15bn¥53.58bn¥52.69bn
Debt—¥10.03bn———¥26.0m——
Shareholders' equity¥140.29bn¥140.33bn¥137.43bn¥135.21bn¥131.15bn¥130.69bn¥130.32bn¥129.11bn

Growth per year

Compound annual rate

3 years5 years10 years
Revenue4.2%2.6%2.4%
Operating income6.1%-3.3%-1.8%
Net income5.9%-1.6%-0.3%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin49.5%50.7%51.7%52.4%
Operating margin8.2%7.6%9.2%9.9%
Net margin6.1%5.8%6.9%7.2%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings15.222.027.417.512.215.533.020.419.820.1
Price to sales1.01.21.21.11.21.31.51.61.71.8

Dividends and splits

Per share, in the currency the company pays

Paid for 36 years. Last went ex-dividend on 29 Sept 2026.

FY2027FY2026FY2025FY2024FY2023FY2022FY2021FY2020
Paid in the year42.50120.0080.0080.0090.0090.0080.0085.00
  • 2-for-1 split · 27 Mar 2019
  • 5-to-1 reverse split · 26 Sept 2013
  • 1.2-for-1 split · 28 Mar 1995
  • 1.2-for-1 split · 28 Mar 1994
  • 1.15-for-1 split · 28 Mar 1989

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.